SR Johnston

658 total citations
19 papers, 328 citations indexed

About

SR Johnston is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, SR Johnston has authored 19 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 6 papers in Genetics. Recurrent topics in SR Johnston's work include Advanced Breast Cancer Therapies (10 papers), Estrogen and related hormone effects (6 papers) and HER2/EGFR in Cancer Research (3 papers). SR Johnston is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), Estrogen and related hormone effects (6 papers) and HER2/EGFR in Cancer Research (3 papers). SR Johnston collaborates with scholars based in United Kingdom, United States and Japan. SR Johnston's co-authors include W. Thompson, S.E.M. Lewis, Valerie J. McKelvey‐Martin, Carmel Hughes, J. Moore, Roger A’Hern, Angela Howes, Paul Workman, Mitch Dowsett and Lisa Patterson and has published in prestigious journals such as Cancer Research, British Journal of Cancer and Annals of Oncology.

In The Last Decade

SR Johnston

18 papers receiving 317 citations

Peers

SR Johnston

ONCOL

GENET

IMMUN

Qiuxia Yan China

Xinkai Cao China

Masaki Okafuji Japan

Xiaowei Xi China

James B. Studd United Kingdom

Iordanis Arzimanoglou United States

Therese Sandberg Sweden

Anja Jacobsen Germany

Xiangyan Jiang China

Hideki Kakiuchi Japan

Qiuxia Yan China

SR Johnston

34 ×0.2

ONCOL

172 ×1.2

61 ×0.8

32 ×0.5

GENET

49 ×0.8

IMMUN

Citations per year, relative to SR Johnston SR Johnston (= 1×) peers Qiuxia Yan

Countries citing papers authored by SR Johnston

Since Specialization

Citations

This map shows the geographic impact of SR Johnston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SR Johnston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SR Johnston more than expected).

Fields of papers citing papers by SR Johnston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by SR Johnston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SR Johnston. The network helps show where SR Johnston may publish in the future.

Co-authorship network of co-authors of SR Johnston

This figure shows the co-authorship network connecting the top 25 collaborators of SR Johnston. A scholar is included among the top collaborators of SR Johnston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with SR Johnston. SR Johnston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Harbeck, Nadia, Valentina Guarneri, Jae Hong Seo, et al.. (2023). 93MO Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer (EBC). ESMO Open. 8(1). 101317–101317. 1 indexed citations

García-Murillas, Isaac, Paula Proszek, Charlotte Fribbens, et al.. (2018). Abstract P2-02-17: Circulating tumor DNA analysis with ultra-high sensitivity sequencing in metastatic breast cancer. Cancer Research. 78(4_Supplement). P2–2.

Leo, Angelo Di, Masakazu Toi, Tammy Forrester, et al.. (2018). Abstract P5-21-02: Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies. Cancer Research. 78(4_Supplement). P5–21. 2 indexed citations

Rastogi, Priya, M. Toi, Nadia Harbeck, et al.. (2018). Abstract OT3-05-05: MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer. Cancer Research. 78(4_Supplement). OT3–5. 3 indexed citations

Nikitorowicz-Buniak, Joanna, Sunil Pancholi, Nikiana Simigdala, et al.. (2018). Abstract P1-09-03: Global knockdown of cellular kinases identifies MPS1 as a novel modulator of endocrine and palbociclib resistance highlighting a new role for MPS1 inhibitors. Cancer Research. 78(4_Supplement). P1–9. 2 indexed citations

Pancholi, Sunil, Ricardo Ribas, Qi Gao, et al.. (2017). Abstract P3-03-09: Resistance to palbociclib depends on multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome. Cancer Research. 77(4_Supplement). P3–3. 21 indexed citations

Nikitorowicz-Buniak, Joanna, et al.. (2016). Abstract P3-05-05: Targeting tumor re-wiring by triple blockade of mTORC1, ERBB and ER signaling pathways in endocrine resistant breast cancer. Cancer Research. 76(4_Supplement). P3–5. 1 indexed citations

Nucíforo, Paolo, Sheeno Thyparambil, Jesús S. Jiménez López, et al.. (2016). Abstract P3-07-08: Quantitative HER family proteins assessment as prognostic and predictive biomarkers in the EGF30008 clinical trial. Cancer Research. 76(4_Supplement). P3–7. 1 indexed citations

Pancholi, Sunil, et al.. (2011). PD01-03: Src Is a Potential Therapeutic Target in Endocrine Resistant Breast Cancer Exhibiting Low Estrogen Receptor (ER)-Mediated Transactivation.. Cancer Research. 71(24_Supplement). PD01–3. 1 indexed citations

10.

Johnston, SR. (2009). Endocrine therapy combined with signal transduction inhibitors – a means to overcome resistance.. Cancer Research. 69(2_Supplement). P1–1. 2 indexed citations

11.

Dowsett, Mitch, et al.. (2009). Lapatinib can activate or supress estrogen receptor (ER) signaling in cell models of endocrine resistant breast cancer.. Cancer Research. 69(2_Supplement). 3031–3031. 3 indexed citations

12.

Karnon, Jonathan, et al.. (2005). PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK. Value in Health. 8(6). A43–A43. 12 indexed citations

13.

Gee, Julia M.W., Anthony Howell, WJ Gullick, et al.. (2005). Consensus Statement. Endocrine Related Cancer. 12(Supplement_1). S1–S7. 32 indexed citations

14.

Drummond, M, et al.. (2001). PCN11: ECONOMIC EVALUATION OF LIPOSOMAL DOXORUBICIN VS TOPOTECAN FOR RECURRENT OVARIAN CANCER IN THE UK. Value in Health. 4(2). 88–88. 1 indexed citations

15.

Kèlland, Lloyd R., Victoria Smith, Melanie Valenti, et al.. (2001). Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.. PubMed. 7(11). 3544–50. 79 indexed citations

16.

Vaughan, Matthew, J. Moore, SR Johnston, et al.. (2000). GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): A phase I trial in melanoma. Annals of Oncology. 11(9). 1183–1190. 13 indexed citations

17.

Johnston, SR, et al.. (1998). Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma. British Journal of Cancer. 77(8). 1280–1286. 65 indexed citations

18.

McKelvey‐Martin, Valerie J., et al.. (1997). Two potential clinical applications of the alkaline single-cell gel electrophoresis assay: (1) human bladder washings and transitional cell carcinoma of the bladder; and (2) human sperm and male infertility. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 375(2). 93–104. 82 indexed citations

19.

Dowsett, Mitch, C. Pfister, SR Johnston, et al.. (1997). 0-73. Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer. The Breast. 6(4). 245–245. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact